Thomas Dayspring: Antihypertensive Class and Dementia Risk
Thomas Dayspring, Lipidologist at Early Medical, shared on LinkedIn:
”Thanks to Kellyann Niotis M.D. for alerting me about the largest multinational cohort study conducted to date investigating different classes of antihypertensive drugs and the risk of incident dementia. The conclusion: physicians and patients should consider the reduced risk of all-cause dementia and Vascular Dementia with ARB compared with ACE-I in their risk–benefit assessment.”
Title: Antihypertensive drug classes and risk of incident dementia: a multinational population-based cohort study
Authors: Edmund C L Cheung, Matthew Adesuyan, Máté Szilcz, Lisa M Kalisch Ellett, Sonia Shah, Yogini H Jani, Sara Hägg, Nicole Pratt, Kui Kai Lau, Hao Luo, Eric Yuk Fai Wan, Esther Wai Yin Chan, Ian C K Wong, Jacqueline K Yuen, Kai-Hang Yiu, Robert Howard, Ruth Brauer, Celine S L Chui
Read the full article here.
Stay updated with Hemostasis Today.
-
Apr 15, 2026, 13:51Matías J Alet: Hospital Carlos Saporiti on the Path to Essential Stroke Center Recognition
-
Apr 15, 2026, 13:39Congratulations to Sandy Middleton for Taking the 2026 HESTA Australian Nursing and Midwifery Awards – Stroke Foundation
-
Apr 15, 2026, 13:25Wolfgang Miesbach: Platelet Variation and How Do They Move Over Time?
-
Apr 15, 2026, 12:44Marwa Elnahas: 4Ts Scoring Tool for Heparin – Induced Thrombocytopenia
-
Apr 15, 2026, 12:27Laurent Bertoletti: Joining Global Experts to Improve Thrombosis Care in Cancer for the ICTHIC 16th Edition
-
Apr 15, 2026, 12:13Francesco Antonio Veneziano: JCDD MDPI Calls for Papers on Advances in Thrombosis and Antithrombotic Therapy
-
Apr 15, 2026, 11:05Julius Kyei Baffour: Understanding Thrombophilia Testing and Patient Risk
-
Apr 15, 2026, 09:10Shall I Bleed Less with Age? Just 2 Weeks Until the Webinar – EHC
-
Apr 15, 2026, 08:51Moustafa Abdou: Sutimlimab is Transforming Outcomes in Cold Agglutinin Disease